Imlygic (talimogene laherparepvec) / Amgen  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

No Longer Available
3b
US
Talimogene Laherparepvec
Amgen
Unresected Stage IIIb to IVM1c Melanoma
 
 
NCT02297529 / 2014-002834-30: Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

No Longer Available
3b
Europe
Talimogene Laherparepvec
Amgen
Unresected Stage IIIB to IVM1c Melanoma
 
 
NCT01161498 / 2010-019071-29: Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Terminated
3
5
US, Europe
Talimogene Laherparepvec, OncoVEX^GM-CSF, IMLYGIC, Radiation, Cisplatin
BioVex Limited, Amgen
Squamous Cell Carcinoma, Head and Neck Cancer
10/11
10/11
OPTiM, NCT00769704: Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Checkmark Approved for unresectable or metastatic melanoma
Dec 2015 - Dec 2015: Approved for unresectable or metastatic melanoma
Checkmark Approved for unresectable melanoma recurrent after initial surgery
Oct 2015 - Oct 2015: Approved for unresectable melanoma recurrent after initial surgery
Checkmark For monotherapy in metastatic melanoma
More
Completed
3
437
US, Canada, Europe, RoW
Talimogene laherparepvec, OncoVEX^GM-CSF, IMLYGIC™, GM-CSF, Leukine, Sargramostim
BioVex Limited, Amgen
Melanoma
02/13
09/14
NCT01368276 / 2010-021070-11: An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
3
31
US, Europe
Talimogene Laherparepvec, OncoVEX^GM-CSF, IMLYGIC™, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
BioVex Limited
Melanoma
09/14
09/14
2016-000317-78: Comparison of PV-10 to Chemotherapy or Oncolytic Viral Therapy for Treatment of Malignant Melanoma of the Skin Confronto tra PV-10 verso chemioterapia o terapia virale oncolitica per il trattamento del melanoma cutaneo localmente avanzato

Not yet recruiting
3
225
Europe
PV-10, Temozolomide, Dacarbazine, Temodal 20 mg capsule rigide, Temodal 100 mg capsule rigide, Temozolamide, TEMODAL, NA, Suspension for injection, Powder for solution for injection, Capsule, hard, Solution for injection, DACARBAZINA MEDAC - 200 MG POLVERE PER SOLUZIONE INIETTABILE O PER INFUSIONE 10 FLACONCINI IN VETRO, Temodal 5 mg capsule rigide, Imlygic 10^6 plaque forming units (PFU)/mL solution for injection, DACARBAZINA MEDAC - 500 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO, TEMODAL - 20 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 100 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 140 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 180 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 250 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, Imlygic 10^8 plaque forming units (PFU)/mL solution for injection
PROVECTUS BIOPHARMACEUTICALS, INC., Provectus Biopharmaceuticals, Inc
Locally Advanced Cutaneous Melanoma Melanoma cutaneo localmente avanzato, Malignant melanoma of skin Melanoma maligno della pelle, Diseases [C] - Cancer [C04]
 
 
NCT02288897: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Terminated
3
20
Europe, US, RoW
PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
Provectus Biopharmaceuticals, Inc.
Cutaneous Melanoma
04/19
09/19

Download Options